Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of NAT2 acetylation phenotype on toxicity in tuberculosis therapy: a systematic review and meta-analysis.

Pharmacogenomics - 1 Jul 2026

Dinegro Sofia, Dal Molin Sara, Mariani Ilaria, Mosini Giulia, Schiuma Marco, Torre Alessandro, Riva Agostino, Gori Andrea, Clementi Emilio, Radice Sonia, Cheli Stefania

Abstract excerpt

INTRODUCTION: Adverse drug reactions (ADRs) remain a major challenge in tuberculosis treatment and frequently compromise therapeutic adherence and outcomes. Hepatotoxicity represents the most clinically significant toxicity. Genetic variability in N‑acetyltransferase 2 (NAT2), the key enzyme involved in isoniazid metabolism, has been associated with toxicity risk, although findings across studies and populations...

Read the complete abstract on PubMed

Topics

Arylamine N-Acetyltransferase
Humans
Antitubercular Agents
Acetylation
Phenotype
Tuberculosis

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Chemical and Drug Induced Liver Injury

Isoniazid

Source

Open in PubMed Open full text

Identifiers

PMID: 42531284
DOI: 10.1080/14622416.2026.2710853
PMCID: PMC13556968

Genes

NAT2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of NAT2 acetylation phenotype on toxicity in tuberculosis therapy: a systematic review and meta-analysis.PMID 42531284Read ↗

Pharmacogenomic insights into tuberculosis treatment shows the NAT2 genetic variants linked to hepatotoxicity risk: a systematic review and meta-analysis.Semantic proximity Read ↗

Efficacy, safety, and pharmacokinetics of isoniazid affected by NAT2 polymorphisms in patients with tuberculosis: A systematic review.Semantic proximity Read ↗

The role of NAT2 genetic variants in anti-tuberculosis drug-induced liver injury (AT-DILI): a meta-analysis.Semantic proximity Read ↗

NAT2 Acetylation Status Predicts Hepatotoxicity During Antituberculosis Therapy: Cumulative Risk Analysis of a Multiethnic CohortSemantic proximity Read ↗

The association between the NAT2 genetic polymorphisms and risk of DILI during anti-TB treatment: a systematic review and meta-analysis.Semantic proximity Read ↗

NAT2 Slow Acetylator Phenotype as a Significant Risk Factor for Hepatotoxicity Caused by Antituberculosis Drugs: Results From a Multiethnic Nested Case-Control Study.Semantic proximity Read ↗

Pharmacogenetics of tuberculosis treatment toxicity and effectiveness in a large Brazilian cohortSemantic proximity Read ↗

Pharmacogenetic association between NAT2 gene polymorphisms and isoniazid induced hepatotoxicity: trial sequence meta-analysis as evidenceSemantic proximity Read ↗

Homozygotes NAT2*5B slow acetylators are highly associated with hepatotoxicity induced by anti-tuberculosis drugs.Semantic proximity Read ↗

NAT2 slow acetylator associated with anti-tuberculosis drug-induced liver injury in Thai patients.Semantic proximity Read ↗

Pharmacogenomic heterogeneity of N-acetyltransferase 2: a comprehensive analysis of real world data in Indian tuberculosis patients and from literature and database review.Semantic proximity Read ↗

NAT2 slow acetylator is associated with anti-tuberculosis drug-induced liver injury severity in indonesian population.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.